Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

(2020) Justin T. Ernst et al.   JOURNAL OF MEDICINAL CHEMISTRY

The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes

(2018) Honyin Chiu et al.   JOURNAL OF IMMUNOLOGY

New Methods To Analyze B Cell Immune Responses to Thymus-Dependent Antigen Sheep Red Blood Cells

(2017) Ellen J. McAllister et al.   JOURNAL OF IMMUNOLOGY

Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment

(2016) Hélène Malka-Mahieu et al.   CLINICAL CANCER RESEARCH

Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism

(2016) Terri N. Iwata et al.   JOURNAL OF IMMUNOLOGY

The 4E-BP–eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes

(2016) Lomon So et al.   Science Signaling

CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A

(2016) Jennifer Chu et al.   Cell Reports

The 4E-BP–eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes

(2016) Lomon So et al.   Science Signaling

Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development

(2015) J. Pelletier et al.   CANCER RESEARCH

Differential Requirements for eIF4E Dose in Normal Development and Cancer

(2015) Morgan L. Truitt et al.   CELL

Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma

(2015) Christos Demosthenous et al.   Oncotarget

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia

(2014) A Schwarzer et al.   ONCOGENE

Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)

(2013) Karolina Nemes et al.   PLoS One

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

(2013) M. Pourdehnad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distinct Translational Control in CD4+ T Cell Subsets

(2013) Eva Bjur et al.   PLoS Genetics

Translational Homeostasis via the mRNA Cap-Binding Protein, eIF4E

(2012) Akiko Yanagiya et al.   MOLECULAR CELL

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

(2008) Michael G. Kharas et al.   JOURNAL OF CLINICAL INVESTIGATION

eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling

(2008) A. Soni et al.   MOLECULAR CANCER THERAPEUTICS